Hydroxyurea or hydroxycarbamide (rINN), (brand names include Hydrea®) is an antineoplastic drug used in hematological malignancies. It also acts as an antiretroviral agent by inhibiting ribonucleotide reductase.

Uses

• Polycythemia vera
• Chronic myelogenous leukemia
• Essential thrombocytosis
• Sickle-cell anemia (selectively breaks down cells that are prone to sickle, as well as increasing fetal hemoglobin content)
• AIDS as an adjunct to ddI in combination antiretroviral therapies

Dose

500 milligrams once or twice a day, or more if pancytopenia does not develop.

Side effects

Reported side-effects are: drowsiness, nausea, vomiting and diarrhea, constipation, mucositis, anorexia, stomatitis, bone marrow toxicity (which may take 7-21 days to recover after the drug has been discontinued), alopecia (hair loss), skin changes, abnormal liver enzymes, creatinine and blood urea nitrogen.

Due to its effect on the bone marrow, regular monitoring of the full blood count is vital, as well as early response to possible infections. In addition, renal function, uric acid and electrolytes, as well as liver enzymes, are commonly checked.

Use in Pregnancy

Category D - investigational or post-marketing data show risk to the fetus. However, potential benefits may outweigh the potential risk. Generally this rating is reserved for drugs with no safer alternatives.

Contraindications

Contraindications are: severe anemia, bone marrow depression or neutropenia.